Metabolic Profiling of Canertinib: A Comprehensive Cross‐Species Investigation Using Advanced UPLC‐MS/MS and LC‐Orbitrap‐HRMS Techniques
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Weiqi Yuan und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu…. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Canertinib is an EGFR tyrosine kinase inhibitor intended for the treatment of leukemia and non–small cell lung cancer. This study described a UPLC‐MS/MS method for quantitatively assessing the metabolic stability of canertinib in liver microsomes. The developed method showed excellent linearity over the concentration range of 10–1000 nM, which is suitable for in vitro high‐throughput screening. Canertinib showed marked species‐dependent metabolism, with CL in vitro, mic following the order: human (28.3 μL/min/mg protein) < rat (48.2 μL/min/mg protein) < monkey (77.8 μL/min/mg protein). An LC‐Orbitrap‐HRMS facilitated structural characterization of the metabolites via accurate mass measurements and MS/MS fragmentation interpretation. Post‐acquisition data‐mining strategies, specifically high‐resolution extracted ion chromatograms and multimass defect filtering, were employed to screen the putative metabolite candidates. Sixteen NADPH‐dependent metabolites and one GSH conjugate were structurally characterized. Cross‐species comparative analysis revealed notable interspecies variations: metabolites M9 and M17 were identified as human‐specific, while M15 and M16 demonstrated monkey‐specificity. The metabolic pathways of canertinib included oxidative defluorination, O ‐dealkylation, oxidative deamination, piperidine ring opening, lactam formation, and GSH conjugation. This work represents the first cross‐species metabolic investigation of canertinib, providing critical insights into interspecies metabolic disparities. The elucidated metabolic framework advances mechanistic understanding of the compound's pharmacological activity and toxicity profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Gang Shi, Jinliang Yang
Zitieren
APA
Yuan, W., Shi, G., Gou, L., & Yang, J. (2025). Metabolic Profiling of Canertinib: A Comprehensive Cross‐Species Investigation Using Advanced UPLC‐MS/MS and LC‐Orbitrap‐HRMS Techniques. Biomedical Chromatography. https://doi.org/10.1002/bmc.70157
Vancouver
Yuan W, Shi G, Gou L, Yang J. Metabolic Profiling of Canertinib: A Comprehensive Cross‐Species Investigation Using Advanced UPLC‐MS/MS and LC‐Orbitrap‐HRMS Techniques. Biomedical Chromatography. 2025. doi:10.1002/bmc.70157
BibTeX
@article{Yuan2025,
author = {Yuan, Weiqi and Shi, Gang and Gou, Lantu and Yang, Jinliang},
title = {Metabolic Profiling of Canertinib: A Comprehensive Cross‐Species Investigation Using Advanced UPLC‐MS/MS and LC‐Orbitrap‐HRMS Techniques},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70157}
}
EUVIMED